NewsBenzingaGenmab A/S annuncia i dati del suo studio di fase 3 LiGeR-HN1 su petosemtamab, che dimostrano una riduzione del 50% del rischio di morte nel trattamento del carcinoma a cellule squamose della testa e del collo. Genmab A/S annuncia i dati del suo studio di fase 3 LiGeR-HN1 su petosemtamab, che dimostrano una riduzione del 50% del rischio di morte nel trattamento del carcinoma a cellule squamose della testa e del collo. Benzinga 2026.10.28 13:45 (GMT+0) Open on Benzinga Other news Billionaire Charlie Munger Called Robinhood ‘A Gambling Parlor Masquerading As a Respectable Business’ and Now They Hold 70 Million Trump Accounts A Strong Q3 Puts Nvidia (NVDA) Stock on Track for a Quick 194% Options Payout As Netflix Stock Hovers Near Its 52-Week Low, Analyst Sentiment Remains Mixed. Here's Why. How to Play General Motors Stock as GM Shares Switch to the Nasdaq British hackers face prison for GTA 6 data breach and crypto thefts Down More Than 60% in 2026, Here Is How You Should Play the Nasty Selloff in AST SpaceMobile Stock
Billionaire Charlie Munger Called Robinhood ‘A Gambling Parlor Masquerading As a Respectable Business’ and Now They Hold 70 Million Trump Accounts